newsfilter
← Earnings
Earnings Releases·

Denali Therapeutics — Third Quarter 2026 Earnings Summary

  • Net product revenue reached $17.8 million in Q3 2026 compared to $0 in the prior year, driving a net income of $70.1 million versus a $126.9 million loss previously; this profit included a one-time $194.0 million gain from a Priority Review Voucher sale.
  • Q4 2026 net product revenue is guided between $30.0 million and $32.0 million, while the company expects to submit a BLA for zafinofusp alfa in 2027 and generate clinical data for five additional TransportVehicle™ programs throughout 2027.
  • AVLAYAH coverage expanded to over 70% of U.S. commercial lives with a permanent J-code effective October 1, 2026, while total liabilities rose to $330 million due to a new $209.7 million revenue participation right agreement.
  • The company maintains a strong liquidity position with approximately $1.0 billion in cash, equivalents, and marketable securities, alongside total assets of $1.26 billion as of September 30, 2026.
Company
DENALI THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology